XML 52 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Segment Information (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 9 Months Ended
Jan. 31, 2014
Jan. 31, 2013
Jan. 31, 2014
Jan. 31, 2013
Net revenue $ 3,690 $ 2,917 $ 9,092 $ 6,481
Sales and marketing costs (821) (658) (2,160) (2,047)
Stock- based compensation expense (941) (570) (1,968) (1,934)
Personalized Oncology Solutions [Member]
        
Net revenue 590 473 1,834 1,850
Direct cost of services (608) (661) (2,078) (2,030)
Sales and marketing costs (405) (361) (1,159) (495)
Other operating expenses 0 0 0 0
Stock- based compensation expense 0 [1] 0 [1] 0 [1] 0 [1]
Segment profit (loss) (423) (549) (1,403) (675)
Translational Oncology Solutions [Member]
        
Net revenue 3,100 2,444 7,258 4,631
Direct cost of services (1,007) (561) (2,572) (1,740)
Sales and marketing costs (352) (220) (812) (636)
Other operating expenses (531) (627) (1,595) (1,463)
Stock- based compensation expense 0 [1] 0 [1] 0 [1] 0 [1]
Segment profit (loss) 1,210 1,036 2,279 792
Unallocated Corporate Overhead [Member]
        
Net revenue 0 0 0 0
Direct cost of services 0 0 0 0
Sales and marketing costs 0 0 0 0
Other operating expenses (1,254) (637) (2,790) (2,418)
Stock- based compensation expense (941) [1] (570) [1] (1,968) [1] (1,934) [1]
Segment profit (loss) (2,195) (1,207) (4,758) (4,352)
Consolidated [Member]
        
Net revenue 3,690 2,917 9,092 6,481
Direct cost of services (1,615) (1,222) (4,650) (3,770)
Sales and marketing costs (757) (581) (1,971) (1,131)
Other operating expenses (1,785) (1,264) (4,385) (3,881)
Stock- based compensation expense (941) [1] (570) [1] (1,968) [1] (1,934) [1]
Segment profit (loss) $ (1,408) $ (720) $ (3,882) $ (4,235)
[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.